FDA Grants Fast Track Designation to SLS009 for Relapsed/Refractory PTCL
The FDA has granted a fast track designation to SLS009 for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma.
Stay updated with breaking news from Life Sciences Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA has granted a fast track designation to SLS009 for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma.
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) was the target of a significant growth in short interest in October. As of October 15th, there was short interest totalling 2,040,000 shares, a growth of 87.2% from the September 30th total of 1,090,000 shares. Based on an average trading volume of 314,700 shares, the […]
The FDA has granted an orphan drug designation to SLS009 for the treatment of patients with acute myeloid leukemia.
By Sabela Ojea Sellas Life Sciences Group said it received an orphan drug designation from the U.S. Food and Drug Administration to treat acute myeloid...
By Sabela Ojea Sellas Life Sciences Group said it received an orphan drug designation from the U.S. Food and Drug Administration to treat acute myeloid leukemia. The clinical...